What happened to the CDC's courage on guns?
As director of the Centers for Disease Control, Dr. Tom Frieden has tweeted and talked about everything from AIDS to obesity to mosquitoes in Hawaii, the overuse of antibiotics, polio in Pakistan, Ebola, sanitation services in East Africa, ambulances in Sierra Leone, premature babies, sexually transmitted diseases, flu shots and World Toilet Day. Sponsored: Drivers With No Tickets In 3 Years Read This Do NOT pay your next car insurance bill until you try this.
Authors: Siamashvili M, Davis S Abstract INTRODUCTION: Bromocriptine mesylate quick release (QR) is a dopamine D2 receptor agonist and is the only oral, primarily centrally acting drug that can be used for the treatment of adults with type 2 diabetes. AREAS COVERED: The authors describe current recommendations on the use of bromocriptine mesylate QR. Major efficacy and safety parameters of the late phase trials, including The Cycloset Safety Trial, have been identified and presented. EXPERT OPINION: Efficacy of bromocriptine mesylate QR monotherapy appears to be low but is compensated by favorable safety pr...
Publication date: Available online 9 October 2020Source: Nutrition, Metabolism and Cardiovascular DiseasesAuthor(s): Vanda Craveiro, Elisabete Ramos, Joana Araújo
Publication date: Available online 10 October 2020Source: Brain, Behavior, and ImmunityAuthor(s): Irene Esteban-Cornejo, Chelsea M. Stillman, Maria Rodriguez-Ayllon, Arthur F. Kramer, Charles H. Hillman, Andrés Catena, Kirk I. Erickson, Francisco B. Ortega
Publication date: Available online 10 October 2020Source: Molecular MetabolismAuthor(s): Holger Henneicke, Sarah Kim, Michael M. Swarbrick, Jingbao Li, Sylvia J. Gasparini, Joanne Thai, Daphne Foong, Lauryn L. Cavanagh, Colette Fong-Yee, Elisabeth Karsten, Ruby C.Y. Lin, Mark S. Cooper, Hong Zhou, Markus J. Seibel
[This Day] Asaba -- Delta State Government has launched the HIV Self-Testing Programme with a vow to scale up all response measures for arresting the relatively high HIV prevalence rate in the state, which places Delta as being among the highest in the country.
CONCLUSION: When gastroenterologists encounter NAFLD/NASH patients, serum CK should be verified. If hyperCKemia, frontal baldness, a hatched face, history of cataract surgery, and grip myotonia are noted, the possibility of MD may be considered. PMID: 33033573 [PubMed]
Authors: Arab JP, Dirchwolf M, Álvares-da-Silva MR, Barrera F, Benítez C, Castellanos-Fernandez M, Castro-Narro G, Chavez-Tapia N, Chiodi D, Cotrim H, Cusi K, de Oliveira CPMS, Díaz J, Fassio E, Gerona S, Girala M, Hernandez N, Marciano S, Masson W, Mendez-Sanchez N, Leite N, Lozano A, Padilla M, Panduro A, Paraná R, Parise E, Perez M, Poniachik J, Restrepo JC, Ruf A, Silva M, Tagle M, Tapias M, Torres K, Vilar-Gomez E, Costa Gil JE, Gadano A, Arrese M Abstract Non-alcoholic fatty liver disease (NAFLD) currently represents an epidemic worldwide. NAFLD is the most frequently diagnosed chr...
Authors: Frías JP Abstract INTRODUCTION: The glucagon-like peptide-1 (GLP-1) receptor agonists (RA) have increasingly gained prominence in the treatment of type 2 diabetes (T2D) based on their glycemic benefits and favorable body weight and cardiorenal effects. Despite this, continued development of therapeutics with superior efficacy is important to help address persistent challenges in the attainment of metabolic goals in many patients with T2D. AREAS COVERED: Tirzepatide is an unimolecular dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RA in development for the treatment of T2D. This re...